Types of first-line hemostatic therapy for all first bleeding episodes [median (IQR)]
| Therapy . | n . | Baseline FVIII level, IU/dL . | Baseline inhibitor titer, BU/mL . | Initial dose, μg/kg or U/kg . | Initial dosing interval, hours . | Total doses per patient, n . | Total dose per patient . |
|---|---|---|---|---|---|---|---|
| rFVIIa | 174 | 2.0 | 15.5 | 90 μg/kg | 3 | 12 | 84 mg |
| (0.0-32.0) | (1.0-2765) | (84.71-102.86) | (2-6) | (3-35) | (24-216 mg) | ||
| aPCC | 63 | 1.0 | 18.0 | 66.67 U/kg | 12 | 8 | 30 000 U |
| (0.0-40.0) | (0.1-1700) | (52.63-82.19) | (12-12) | (3-15) | (12 000-56 000 U) | ||
| FVIII | 56 | 3.0 | 7.5 | 52.91 U/kg | 12 | 5 | 20 000 U |
| (0.0-34.0) | (0.8-180) | (40.00-81.97) | (8-12) | (2-10) | (9000-49 500 U) | ||
| DDAVP | 14 | 3.5 | 8.0 | 0.3 μg/kg | 12 | 2.5 | 40 μg |
| (0.0-17.0) | (0.3-200) | (0.3-0.3) | (8-24) | (1-3) | (21-64 μg) |
| Therapy . | n . | Baseline FVIII level, IU/dL . | Baseline inhibitor titer, BU/mL . | Initial dose, μg/kg or U/kg . | Initial dosing interval, hours . | Total doses per patient, n . | Total dose per patient . |
|---|---|---|---|---|---|---|---|
| rFVIIa | 174 | 2.0 | 15.5 | 90 μg/kg | 3 | 12 | 84 mg |
| (0.0-32.0) | (1.0-2765) | (84.71-102.86) | (2-6) | (3-35) | (24-216 mg) | ||
| aPCC | 63 | 1.0 | 18.0 | 66.67 U/kg | 12 | 8 | 30 000 U |
| (0.0-40.0) | (0.1-1700) | (52.63-82.19) | (12-12) | (3-15) | (12 000-56 000 U) | ||
| FVIII | 56 | 3.0 | 7.5 | 52.91 U/kg | 12 | 5 | 20 000 U |
| (0.0-34.0) | (0.8-180) | (40.00-81.97) | (8-12) | (2-10) | (9000-49 500 U) | ||
| DDAVP | 14 | 3.5 | 8.0 | 0.3 μg/kg | 12 | 2.5 | 40 μg |
| (0.0-17.0) | (0.3-200) | (0.3-0.3) | (8-24) | (1-3) | (21-64 μg) |